A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 80
Summary
- Conditions
- Advanced Breast Cancer
- HER2 Amplified
- Human Epidermal Growth Factor Receptor 2 (HER2)
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02091960
- Collaborators
- Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
- Investigators
- Study Director: Executive Medical Director Astellas Pharma Global Development, Inc.
Get Well Soon